Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

Schmidt PHS, de Souza VSN, Machado LG, Rodrigues JVA, da Cruz JVR, de Souza LSN, Dos Santos BE, Hohl A, Ronsoni MF, van de Sande-Lee S

Diabetes, obesity & metabolism18 Feb 2026Cited by 2 (Europe PMC)

PMID41705736DOI10.1111/dom.70529PepBankPUB-41705736

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in adults with overweight or obesity, tirzepatide improved SF-36 physical function more than placebo (MD 2.26 points).
In plain wordsIn pooled trials of adults with overweight or obesity, tirzepatide improved self-reported physical function more than placebo.
Peptide
Tirzepatide
Outcome
IncreaseSF-36 physical function versus placebo
Study
n = 4,531
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Whole body
Studied dose
10 or 15 mg once weeklyAs given in this study (human).
Measurements
MD
2.26 points
SF-36 physical function
95% CI
1.76 to 2.76 points
SF-36 physical function
Source sentences
Summary
SF-36 physical function (MD 2.26 points; 95% CI, 1.76-2.76; I² = 99.8%; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes.
Summary · context
Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included.
Report a problemFND-4170573601
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in adults with overweight or obesity, tirzepatide improved IWQOL-Lite-CT physical function more than placebo (MD 10.10 points).
In plain wordsIn pooled trials of adults with overweight or obesity, tirzepatide improved weight-related physical function scores more than placebo.
Peptide
Tirzepatide
Outcome
IncreaseIWQOL-Lite-CT physical function versus placebo
Study
n = 4,531
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Whole body
Studied dose
10 or 15 mg once weeklyAs given in this study (human).
Measurements
MD
10.1 points
IWQOL-Lite-CT physical function
95% CI
8.61 to 11.6 points
IWQOL-Lite-CT physical function
Source sentences
Summary
IWQOL-Lite-CT physical function (MD 10.10 points; 95% CI, 8.61-11.60; I² = 99.8%; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes.
Summary · context
Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included.
Report a problemFND-4170573602
03HumanSystematic reviewEfficacy outcome
In subgroup analysis by dose, the 10 mg tirzepatide group showed consistent improvement in physical function.
In plain wordsIn pooled trials, the 10 mg tirzepatide group showed better physical function scores than placebo.
Peptide
Tirzepatide
Outcome
IncreasePhysical function at tirzepatide 10 mg (subgroup)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Whole body
Studied dose
10 mgAs given in this study (human).
Source sentences
Summary
Subgroup analyses by dose demonstrated consistent benefits for both 10 and 15 mg groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes.
Summary · context
Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included.
Report a problemFND-4170573603
04HumanSystematic reviewEfficacy outcome
In subgroup analysis by dose, the 15 mg tirzepatide group showed consistent improvement in physical function.
In plain wordsIn pooled trials, the 15 mg tirzepatide group showed better physical function scores than placebo.
Peptide
Tirzepatide
Outcome
IncreasePhysical function at tirzepatide 15 mg (subgroup)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Whole body
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
Subgroup analyses by dose demonstrated consistent benefits for both 10 and 15 mg groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tirzepatide 10 or 15 mg with placebo and reporting validated physical function outcomes.
Summary · context
Six RCTs comprising 4531 participants, of whom 2802 underwent tirzepatide treatment were included.
Report a problemFND-4170573604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.